Four Huntington’s Disease Therapies Racing to Catch Up with UniQure
4 Huntington’s Therapies Chasing UniQure Last month, “historic positive results” from uniQure’s gene therapy snapped the Huntington’s community out of years of failure. As the biotech prepares to submit for…
UniQure’s Huntington’s Breakthrough Offers New Hope for Patients, Though Experts Advise Caution
UniQure’s Huntington’s Breakthrough Brings Hope to Patients but Experts Urge Caution Pivotal results from uniQure’s gene therapy for Huntington’s disease have brought new light to patients who have known only…
Regeneron Drops 2seventy’s CAR T Cell Therapy for Lymphoma in Strategic Shift
Regeneron Cans 2seventy-Acquired CAR T Candidate for Lymphoma in ‘Strategic’ Move The discontinued CAR T therapy bbT369 came to Regeneron when the pharma bought all of 2seventy bio’s pipeline assets…
Lilly Strengthens Gene Therapy Pipeline With Up to $262 Million Adverum Acquisition
Lilly Dives Deeper Into Gene Therapy With up to $262M Adverum Buy The cornerstone of the deal is Ixo-vec, an intravitreal gene therapy currently in Phase III development for wet…
Biogen Expands Immunology Portfolio With $70 Million Deal for Vanqua’s Anti-Inflammatory Drug
Biogen Grows Immunology Pipeline With Vanqua’s Anti-Inflammatory Molecule Biogen has licensed Vanqua Bio’s preclinical oral C5aR1 antagonist in a bid to pump up its immunology pipeline.Under the terms of the…
China’s NMPA Accepts New Drug Application for HS-10365 Capsules to Treat RET Fusion-Positive NSCLC
CHINA NMPA ACCEPTS NEW DRUG APPLICATION FOR HS-10365 CAPSULES FOR THE TREATMENT OF RET FUSION-POSITIVE NSCLC Hansoh Pharmaceutical Group Co., Ltd. (Hansoh Pharma, 03692.HK) today announces that the New Drug…
Arcturus Shares Drop on ‘Mixed’ Results for Inhaled mRNA Therapy in Cystic Fibrosis
Arcturus Plunges on ‘Mixed’ Cystic Fibrosis Data for Inhaled mRNA Drug Arcturus Therapeutics’ inhaled mRNA therapy ARCT-032 failed to show meaningful improvements in lung function in a Phase II trial…
MERS-CoV Added to WHO BioHub to Boost Research and Preparedness
MERS-CoV virus isolate added to the WHO BioHub System, enabling further research and pandemic preparedness Through the BioHub, countries can voluntarily share and request biological materials with epidemic or pandemic…
Biotech Markets Show Signs of Recovery—but Analysts Warn It’s Too Soon to Celebrate
Biotech Markets Turn Positive but Experts Say Don’t Call It a Comeback—Yet M&A is back, the S&P XBI is rising again, a biotech pulled off an IPO and positive data…
Leadership Lab: Spotting Early Signs of Employee Turnover in Biopharma
Leadership Lab: How To Spot When Employees Are About To Walk Away Employees rarely leave companies for one reason alone. In this column, Kaye/Bassman’s Michael Pietrack shares a framework that…
WuXi Biologics Receives 2025 Global Customer Value Leadership Award from Frost & Sullivan
Recognition highlights WuXi Biologics’ commitment to delivering exceptional value and innovative solutions to its global clients. WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today…
IDWeek 2025: Shionogi Highlights Data Supporting Cefiderocol’s sRole in Tough-to-Treat Infections
New findings underscore Cefiderocol’s efficacy and reliability in managing complex, multidrug-resistant bacterial infections. Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) presents…